Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TS-161 in Treatment-Resistant Depression
NCT04821271Phase 2Terminated
- Sponsor
- National Institute of Mental Health
- Start
- Jun 2021
- Primary completion
- May 2024
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TP0473292 in major depressive disorder (MDD), sponsored by National Institute of Mental Health. Started Jun 2021; status: terminated.
02
Drugs
TP0473292
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04821271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04821271.